FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17 18 Next >>
 
TXT Chimerix Plans Accelerated Approval NDA for Gliomas Drug
12/09/2024
 
 
TXT Fresenius Hit With 11-Item FDA-483
12/09/2024
 
 
TXT e-Submission Guide for BIMO Inspection Planning
12/06/2024
 
 
TXT Panel to Discuss Opioid Abuse Studies
12/06/2024
 
 
TXT Drug/Biologic Accelerated Approval Draft Guide
12/06/2024
 
 
TXT GE Healthcare Recalls Newborn Incubators
12/06/2024
 
 
TXT Groups Urge Rare Disease Voucher Reauthorization
12/06/2024
 
 
TXT FDA Loses Again in FOIA Suit on Vaccine Records
12/06/2024
 
 
TXT Syndax Leukemia Review Extended by FDA
07/29/2024
 
 
TXT NEWSROOM CLOSED FOR THE HOLIDAYS
12/18/2023
 
 
TXT FDA OKs Merck Kidney Cancer Drug
12/17/2023
 
 
TXT FDA OKs Glaukos Intraocular Pressure Drug Implant
12/17/2023
 
 
TXT 2 Imbruvica Accelerated Approvals Withdrawn
12/17/2023
 
 
TXT DTC Survey Examines Quantitative Claims
12/17/2023
 
 
TXT FDA Updates Breast Implant Safety Info
12/17/2023
 
 
TXT Guide on Priority Zoonotic Animal Drugs
12/17/2023
 
 
TXT Moderna Inspection Cites GMP Issues: Report
12/17/2023
 
 
TXT FDA Warns Makers of Illegal Animal Antimicrobials
12/14/2023
 
 
TXT FDA in 3 More Collaborative Communities
12/14/2023
 
 
TXT House Committee Threatens FDA Subpoena
12/14/2023
 
 
TXT FDA ‘Doing Little’ on Social Media Drug Claims: Report
12/14/2023
 
 
TXT Pharmasol Permanent Injunction Approved
12/14/2023
 
 
TXT Clinical Hold on 3 CARsgen CAR T-cell Therapies
12/14/2023
 
 
TXT Stakeholder Technical Issues with Ophthalmic Guide
12/14/2023
 
 
TXT FDA Approves Neuroblastoma Drug
12/14/2023
 
 
TXT Update GAO Device Recall Oversight Report: Senators
12/13/2023
 
 
TXT Novid Distributing Unapproved, Misbranded Drug: FDA
12/13/2023
 
 
TXT Guide on Advanced Manufacturing Tech
12/13/2023
 
 
TXT Regulatory Affairs, Foods Program Under Review
12/13/2023
 
 
TXT HELP Committee OKs EFFECTIVE Opioid Bill
12/13/2023
 
 
TXT GOP Senators Urge Increase in Foreign Inspections
12/13/2023
 
 
TXT Amgen Files Priority BLA for Lung Cancer
12/13/2023
 
 
TXT AdvaMed Faults FDA on ‘Safety’ 510(k) Guidances
12/13/2023
 
 
TXT Supreme Court Agrees to Hear Mifepristone Case
12/13/2023
 
 
TXT New Genetic Metabolic Disease Treatment A/C
12/12/2023
 
 
TXT Strengthen Botox Safety Warning: Public Citizen
12/12/2023
 
 
TXT Advanced Manufacturing Technologies Guidance
12/12/2023
 
 
TXT Dolor Tech Settles Over Migraine Device
12/12/2023
 
 
TXT Peptide Clinical Pharmacology Guidance
12/12/2023
 
 
TXT Risk-Based Approach to Therapeutic Protein DDI
12/12/2023
 
 
TXT CDISC Study Tabulation Model Version 3.4
12/12/2023
 
 
TXT FDA May Not be Ready for LDT Rule: Attorney
12/12/2023
 
 
TXT Oncology Drug Dose Optimization Often Deferred: Analysis
12/12/2023
 
 
TXT First Psychedelic NDA Filing Claimed for PTSD Therapy
12/12/2023
 
 
TXT Trump Aligned Group Sues FDA on Ivermectin
12/11/2023
 
 
TXT Guide on DTC Quantitative Efficacy/Risk Info
12/11/2023
 
 
TXT Device CEO Pleads Guilty in Covid Test Scheme
12/11/2023
 
 
TXT FDA Requiring Less Burdensome Isotretinoin REMS
12/11/2023
 
 
TXT NDA Resubmission on Hypoparathyroidism Accepted
12/11/2023
 
 
TXT PETA Letter Hits at FDA Lab Animal 'Cruelty'
12/11/2023
 
 
TXT Pfizer BLA for Hemophilia Accepted for Review
12/11/2023
 
 
TXT First Sickel Cell Gene Therapies Approved
12/08/2023
 
 
TXT Novartis Reports Risk Reduction Kisqali Data
12/08/2023
 
 
TXT Guide on Drug Supply Chain Security
12/08/2023
 
 
TXT Getinge Recalls CardioHelp Emergency Drive
12/08/2023
 
 
TXT Info Collection on OTC Drugs
12/08/2023
 
 
TXT Cardinal Health Recalls Procedure Kits
12/08/2023
 
 
TXT Section 503B Compounding Enforcement Discretion
12/07/2023
 
 
TXT FDA Clears BD ‘Novel’ Blood Sampler
12/07/2023
 
 
TXT Bill to Establish HHS Generic Drug Manufacturer
12/07/2023
 
 
TXT Positive Phase 1/2 Linvoseltamab Results to FDA
12/07/2023
 
 
TXT Pediatric Drug Development Bill Introduced
12/07/2023
 
 
TXT Action Against BPI Methylene Blue Injection Asked
12/07/2023
 
 
TXT Restrict ANDAs for Generic Xipere: Bausch & Lomb
12/07/2023
 
 
TXT Merck Halts Keytruda Lung Cancer Trial
12/07/2023
 
 
TXT Pro Publica Slams FDA on Respirator Recall
12/07/2023
 
 
TXT Alpha Cognition NDA for Alzheimer’s Filed
12/07/2023
 
 
TXT FDA Sets Bulk Substance Compounding Policy
12/06/2023
 
 
TXT FDA Grants, Denies Provepharm ProvayBlue Petition
12/06/2023
 
 
TXT Novartis’ Fabhalta for PNH Approved
12/06/2023
 
 
TXT Probe FDA ‘Cozy Relationship’ with Pharma: Rep. Harris
12/06/2023
 
 
TXT Restrict ANDAs for Generic Zoryve: Arcutis
12/06/2023
 
 
TXT eSTAR e-Submissions Open for PMAs
12/06/2023
 
 
TXT CBER Helping to Speed Gene Therapies: Marks
12/06/2023
 
 
TXT Opdivo sBLA for Bladder Cancer
12/06/2023
 
 
TXT Animal Drug Regulations Amended
12/06/2023
 
 
TXT Industry Concerns with Predicate Device Guide
12/06/2023
 
 
TXT Review Extended on Sinus Drug
12/06/2023
 
 
TXT Providence Medical Tech Cavux Facet Device Cleared
12/16/2022
 
 
TXT FDA OK’s Ferring’s Bladder Cancer Gene Therapy
12/16/2022
 
 
TXT Panel to Examine Ongoing Covid Vaccine Modifications
12/16/2022
 
 
TXT Contractor Conflict-of Interest Bill Passes Congress
12/16/2022
 
 
TXT Aurigene Ditches Psoriasis Drug Candidate
12/16/2022
 
 
TXT FDA Updates CRL Guidance Performance Goals
12/15/2022
 
 
TXT Comments on Immune-Mediated Adverse Reaction Guidance
12/15/2022
 
 
TXT Independent FDA Needed to Stop Political Meddling: GAO
12/15/2022
 
 
TXT Draft Guide on Pulmonary Tuberculosis Drugs
12/15/2022
 
 
TXT Draft Inspection Refusal Guidance
12/15/2022
 
 
TXT FDA Stem Cell Therapy Regulation at Risk: Attorneys
12/15/2022
 
 
TXT States Pushing for Canadian Drug Imports: Report
12/14/2022
 
 
TXT Harmonize Innovative Manufacturing Regulation: PhRMA
12/14/2022
 
 
TXT AdvaMed Supports Breakthrough Device Guidance Updates
12/14/2022
 
 
TXT VALID Could Hurt Home Sample Testing: Attorneys
12/14/2022
 
 
TXT Former NECC Ops Director Sentenced to 5 Months in Jail
12/14/2022
 
 
TXT FDA Panel Thumbs Down on Heart Failure Drug
12/14/2022
 
 
TXT FDA Accepts NDA for Eye Dilating Combo Product
12/13/2022
 
 
TXT $2.25 mil. RWD Funding Opportunity
12/13/2022
 
 
TXT CGMP Deviations Seen in Centrient Inspection
12/13/2022
 
 
TXT Clinicians Need Refresher on Clinical Trial Statistics: Survey
12/13/2022
 
 
TXT What’s Behind the New LASIK Guidance?
12/13/2022
 
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17 18  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving